Elusive sources of variability of dystrophin rescue by exon skipping

Skeletal Muscle

Volumn 5, Issue 1, 2015, Pages

  Vila, Maria Candida ^a,b   Klimek, Margaret Benny ^a   Novak, James S ^a   Rayavarapu, Sree ^a   Uaesoontrachoon, Kitipong ^a   Boehler, Jessica F ^a,b   Fiorillo, Alyson A ^a   Hogarth, Marshall W ^a   Zhang, Aiping ^a   Shaughnessy, Conner ^a   Gordish Dressman, Heather ^a,b   Burki, Umar ^c   Straub, Volker ^c   Lu, Qi Long ^d   Partridge, Terence A ^a,b   Brown, Kristy J ^a,b   Hathout, Yetrib ^a,b   van den Anker, John ^a,e   Hoffman, Eric P ^a,b   Nagaraju, Kanneboyina ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d CAROLINAS MEDICAL CENTER   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Duchenne muscular dystrophy; Dystrophin; Exon skipping; Mdx 23; Variability

Indexed keywords

EID: 84949238400     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/s13395-015-0070-6     Document Type: Article

References (45)

1. Hoffman EP. Genotype/phenotype correlations in Duchenne/Becker dystrophy. Mol Cell Biol Hum Dis Serv 1993;3:12-36.
2. Hoffman EP, Monaco AP, Feener CC, Kunkel LM. Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science. 1987; 238(4825):347-50.
3. Hoffman EP, Schwartz L. Dystrophin and disease. Mol Aspects Med. 1991; 12(3):175-94.
4. Roses AD, Herbstreith MH, Appel SH. Membrane protein kinase alteration in Duchenne muscular dystrophy. Nature. 1975;254(5498):350-1.
5. Hutter OF, Burton FL, Bovell DL. Mechanical properties of normal and mdx mouse sarcolemma: bearing on function of dystrophin. J Muscle Res Cell Motil. 1991;12(6):585-9.
6. Menke A, Jockusch H. Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature. 1991;349(6304):69-71.
7. Menke A, Jockusch H. Extent of shock-induced membrane leakage in human and mouse myotubes depends on dystrophin. J Cell Sci. 1995;108 (Pt 2):727-33.
8. Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle cells. J Cell Biol. 1995;128(3):355-61.
9. Emery AE. The muscular dystrophies. Lancet. 2002;359(9307):687-95.
10. Gilroy J, Cahalan JL, Berman R, Newman M. Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy. Circulation. 1963;27(4 Pt 1):484-93.
11. Melacini P, Vianello A, Villanova C, Fanin M, Miorin M, Angelini C, et al. Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy. Neuromuscul Disord. 1996;6(5):367-76.
12. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child. 2008;93(11):986-90.
13. Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve. 2013;48(1):27-31.
14. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177-89.
15. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93.
16. Wood MJ, Gait MJ, Yin H. RNA-targeted splice-correction therapy for neuromuscular disease. Brain. 2010;133(Pt 4):957-72.
17. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A. 2005;102(1):198-203.
18. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med. 2006;12(2):175-7.
19. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol. 2009;65(6):667-76.
20. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378(9791):595-605.
21. Wu B, Lu P, Benrashid E, Malik S, Ashar J, Doran TJ, et al. Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther. 2010;17(1):132-40.
22. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther. 2010;18(11):1995-2005.
23. Malerba A, Sharp PS, Graham IR, Arechavala-Gomeza V, Foster K, Muntoni F, et al. Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther. 2011;19(2):345-54.
24. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8(10):918-28.
25. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637-47.
26. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med. 2011;364(16):1513-22.
27. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014;13(10):987-96.
28. Yokota T, Pistilli E, Duddy W, Nagaraju K. Potential of oligonucleotidemediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2007;7(6):831-42.
29. Sharp PS, Bye-a-Jee H, Wells DJ. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther. 2011;19(1):165-71.
30. Sazani P, Van Ness KP, Weller DL, Poage D, Nelson K, Shrewsbury SB. Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice. Int J Toxicol. 2011;30(3):322-33.
31. Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR, et al. Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol. 2011; 179(1):12-22.
32. Hoffman EP, McNally EM. Exon-skipping therapy: a roadblock, detour, or bump in the road. Sci Transl Med. 2014;6(230):230fs14.
33. Fiorillo AA, Heier CR, Novak JS, Tully CB, Brown KJ, Uaesoontrachoon K, et al. TNF-alpha-Induced microRNAs control dystrophin expression in Becker muscular dystrophy. Cell Rep. 2015;12:1678-90.
34. Baudy AR, Sali A, Jordan S, Kesari A, Johnston HK, Hoffman EP, et al. Noninvasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging. Mol Imaging Biol. 2011;13(3):462-70.
35. Zhang A. The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse. Toxic Rep. 2015;2:838-49.
36. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, et al. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve. 2009;39(5):591-602.
37. Kesari A, Fukuda M, Knoblach S, Bashir R, Nader GA, Rao D, et al. Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset. Am J Pathol. 2008;173(5):1476-87.
38. Goodman CA, Kotecki JA, Jacobs BL, Hornberger TA. Muscle fiber typedependent differences in the regulation of protein synthesis. PLoS ONE. 2012;7(5):e37890.
39. Brown KJ, Marathi R, Fiorillo AA, Ciccimaro EF, Sharma S, Rowlands DS et al. Accurate quantitation of dystrophin protein in human skeletal muscle using mass spectrometry. J Bioanal Biomed. 2012;Suppl 7.
40. Rayavarapu S, Coley W, Cakir E, Jahnke V, Takeda S, Aoki Y, et al. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Mol Cell Proteomics. 2013;12(5):1061-73.
41. Sharma N, Medikayala S, Defour A, Rayavarapu S, Brown KJ, Hathout Y, et al. Use of quantitative membrane proteomics identifies a novel role of mitochondria in healing injured muscles. J Biol Chem. 2012;287(36):30455-67.
42. Burki U, Keane J, Blain A, O'Donovan L, Gait MJ, Laval SH, et al. Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides. Nucleic Acid Ther. 2015;25:275-84.
43. Mittendorfer B, Andersen JL, Plomgaard P, Saltin B, Babraj JA, Smith K, et al. Protein synthesis rates in human muscles: neither anatomical location nor fibre-type composition are major determinants. J Physiol. 2005;563(Pt 1): 203-11.
44. Savary I, Debras E, Dardevet D, Sornet C, Capitan P, Prugnaud J, et al. Effect of glucocorticoid excess on skeletal muscle and heart protein synthesis in adult and old rats. Br J Nutr. 1998;79(3):297-304.
45. Dadgar S, Wang Z, Johnston H, Kesari A, Nagaraju K, Chen YW, et al. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. J Cell Biol. 2014;207(1):139-58.